Potassium, Hydration, Cardiovascular, and Kidney Study (PHACKs)

Launched by AUBURN UNIVERSITY · Sep 25, 2023

Keywords

ClinConnect Summary

The Potassium, Hydration, Cardiovascular, and Kidney Study is investigating how hydration and potassium intake can affect heart and kidney health, particularly in young Black adults compared to young White adults. Researchers believe that many Black individuals may not drink enough water and consume less potassium, which can lead to higher blood pressure and increase the risk of heart and kidney diseases. This trial aims to see if drinking bottled water with a potassium supplement for 14 days can improve hydration and cardiovascular health.

To participate in this study, you need to be between 18 and 30 years old, have a resting blood pressure no higher than 150/90 mmHg, and a body mass index (BMI) below 35. You should also be free from certain health conditions, like diabetes and heart disease. If you join, you'll be monitored before and after the 14-day period to check your blood pressure, blood samples, and other health markers. This study is currently recruiting participants and aims to not only find effective health strategies but also understand how factors like income and access to resources may affect hydration and health outcomes.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Between the ages of 18-30 years
• • Resting blood pressure no higher than 150/90 mmHg
• • BMI below 35 kg/m2
• • Free of any metabolic disease (e.g., diabetes) kidney disease, pulmonary disorders (e.g., COPD), cardiovascular disease (peripheral vascular, cardiac, or cerebrovascular), no autoimmune diseases, and no history of cancer.
• Exclusion Criteria:
• • Have any precluding medical conditions (i.e. hemophilia) or medication (Pradaxa, Eliquis, etc.) that prevent participants from giving blood.
• • Are currently pregnant or trying to become pregnant.
• * take any of the following medications that are contraindicated with potassium supplementation:
• • Renin-angiotensin-aldosterone system (RAAS) blockers: Candesartan , Eprosartan, Irbesartan, Losartan, Olmesartan, Telmisartan
• • Non -steroidal anti-inflammatory medications: Aspirin, Ibuprofen, Naproxen
• • Non-selective beta-blockers: Pindolol, Penbutolol, Oxprenolol, Propranolol, Nadolol, Sotalol, Timolol, Tertatolol
• • Calcineurin inhibitors: Cyclosporine
• • Heparin (or other blood thinning medications)